The Breast Cancer Prevention Coalition of the CSRA will recognize the research efforts of Drs. Ahmed Chadli, Ravindra Kohle, and Lesleyann Hawthorn at 3:30 p.m. Friday, Aug. 9, during a reception at the GRU Cancer Center Clinical Building, 1411 Laney Walker Blvd. The program will include a synopsis of each researcher’s current work and the presentation of approximately $90,000 in research funding by the coalition.
Chadli is a member of the Molecular Oncology and Biomarkers program at the GRU Cancer Center. His current research focuses on a recently characterized and highly aggressive breast cancer – molecular apocrine breast cancer – and the role androgen receptors play in the growth of these tumors.
Kolhe is the Laboratory Director of the Georgia Esoteric and Molecular Diagnostic Labs in Pathology at GRU and a member of the Clinical Oncology program at the GRU Cancer Center. His current research focuses on the role of immune system inhibitors in breast tumor growth and, ultimately, treatment.
Hawthorn is Director of GRU Cancer Center Shared Resources and a member of the Molecular Oncology and Biomarkers team. Her current research focuses on the molecular profiling of aggressive Triple Negative breast cancers in the African-American population. This tumor type has proven particularly aggressive in African-American women, and this research is an important component of the GRU Cancer Center’s disparity research goals.
The GRU Cancer Center is a multi-disciplinary academic cancer center focused on both research and clinical treatment. Its patient-centered approach to treatment includes first-in-the-nation treatment protocols, an experimental therapeutics program that includes specialized clinics for Phase I trials and immunotherapy, and a variety of ancillary programs – including music therapy and genetic counseling – designed with holistic healing in mind.